These findings may provide insight into our observation that around 50% of IRX3high cases of AML lack expression of FTO-lncAML; here IRX3 expression might be promoted through interaction with the CRNDE-IRX5 locus rather than intron 8 of FTO, although once more the upstream mechanisms driving activation are unclear. This evidence concerns the gene IRX3 and acute myeloid leukemia.